Citations 2
Tumor necrosis factor‐α inhibitor‐induced morphea and psoriasiform dermatitis in a pediatric patient with Crohn's disease
Reinhart, Jacob P. , Aird, Jenna, Stephens, Michael C., Asch, Sarah , Orandi, Amir B. , Tollefson, Megha M. , Aird, Jenna L., Orandi, Amir B , Reinhart, Jacob
Pediatric Dermatology | November 17, 2022 | Volume: 40 | Issue: 3 | Pages: 519-522
AbstractTumor necrosis factor‐alpha inhibitor therapy for inflammatory bowel disease may be associated with paradoxical cutaneous adverse events, most commonly psoriasiform eruptions. We present the case of a pediatric female patient with Crohn's disease who developed multiple concurrent cutaneous eruptions while on infliximab treatment, including morphea, psoriasiform dermatitis, and genital lichen sclerosus. Although refractory to skin‐directed treatments, all three conditions resolved upon discontinuation of infliximab, supporting their development as a paradoxical reaction to infliximab therapy.
Palliative care utilization in calciphylaxis: a single‐center retrospective review of 121 patients (1999–2016)
Gaster, Emily E., Riemer, Christie , Aird, Jenna L., King, Brian J. , Wilson, Barbara, Strand, Jacob J. , Wu, Kelly L. , Cleary, James F. , Lohse, Christine M. , Lehman, Julia S. , Riemer, Christie A, El-Azhary, Rokea A, Wu, Kelly L , Lehman, Julia S , Gaster, Emily E, Aird, Jenna, el‐Azhary, Rokea A.
International Journal of Dermatology | July 2, 2021 | Volume: 61 | Issue: 4 | Pages: 455-460
AbstractBackgroundCalciphylaxis is a debilitating dermatological condition associated with high rates of morbidity and mortality. Palliative care offers a multidisciplinary approach to addressing symptoms and goals of care in patients with serious medical diagnoses. Involvement of palliative services for calciphylaxis is infrequently reported in the literature. The purpose of this report is to assess rates of palliative and pain consultation for patients with calciphylaxis.MethodsThis is a comprehensive, single‐institution retrospective chart review of 121 eligible patients with a diagnosis of calciphylaxis treated at Mayo Clinic in Rochester, Minnesota, from 1999 to 2016. Inclusion criteria were an indisputable diagnosis of calciphylaxis based on clinical, histopathologic, and radiographic features. One hundred twenty‐one patients met inclusion criteria.ResultsFifty‐one patients (42%) received either a palliative (n = 15) or pain (n = 20) consultation, or both (n = 16). Patients with a palliative care consultation were younger compared with those without (mean ages 57 vs. 62 years, P = 0.046). In 104 patients (86%), psychiatric symptoms were not assessed.ConclusionsIn this cohort of patients with calciphylaxis, the majority do not receive palliative and pain care consultations. Psychiatric complications are inconsistently addressed. These observations highlight practice gaps in the care of patients with calciphylaxis.